Visit booth 409 at #RAPSConvergence2025 to meet ICON’s Regulatory Affairs team. Stop by to discuss how we can support your regulatory strategy, CMC, project management, medical device and post-market requirements across ...
Immuno-oncology
Gain a competitive edge in immunotherapy trials
Transforming immuno-oncology trial design is critical to success
As proof of their effectiveness has grown, immunotherapies have rapidly gained popularity in recent years. These approaches have the potential to reduce safety concerns, have a higher therapeutic index and tackle a breadth of targets including solid tumours. For example, allogeneic CAR-T cell therapies manufactured using T cells from just one healthy donor can be sufficient to create therapeutic doses to treat more than 20 adult patients.
With the advent of these promising therapies, the field of oncology continues to evolve quickly and calls for novel approaches to clinical trials. Staying competitive in this increasingly crowded field will require sponsors to adopt nontraditional, flexible trial designs to enhance cost efficiency and reduce patient burden.
ICON Immuno-oncology experience in the past five years:
-
418
Studies conducted -
55,840+
Patients involved -
18,880+
Sites worldwide
ICON's immuno-oncology experience in all development phases over the past five years includes indications in leukemia, lymphoma, NSCLC, pancreatic cancer and solid tumours.
Successfully implementing the required trial design strategies will require substantial expertise that many sponsors do not have in house. Contact us to learn more about our:
- Experience in the development of immunotherapies, such as CAR-T therapies
- Custom assay development for assessing efficacy and safety of therapies
- Patient-centric approach to immuno-oncology trials
- Early phase expertise
- Biotech partnerships
Oncology insights
ICON's Oncology experts provide analysis including whitepapers, blogs and contributions to media and industry conversations relating to all aspects of oncology in clinical trials.
